

REACH HIGHER

With the Long-lasting
Protection of AFSTYLA

FREE educational webinars!
Participate from the
comfort of your HOME.

*Anyone under 18 years of age must be
accompanied by a parent or caregiver.*

To find a list of our upcoming
webinars and to register for one,
visit us online or give us a call!



Online: www.CommonConnectionsHemA.com

Phone: 1-866-992-9940

Important Safety Information

AFSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, is used to treat and control bleeding episodes in people with hemophilia A. Used regularly (prophylaxis), AFSTYLA can reduce the number of bleeding episodes and the risk of joint damage due to bleeding. Your doctor might also give you AFSTYLA before surgical procedures.

AFSTYLA is administered by intravenous injection into the bloodstream, and can be self-administered or administered by a caregiver. Your healthcare provider or hemophilia treatment center will instruct you on how to do an infusion. Carefully follow prescriber instructions regarding dose and infusion schedule, which are based on your weight and the severity of your condition.

Do not use AFSTYLA if you know you are allergic to any of its ingredients, or to hamster proteins. Tell your healthcare provider if you previously had an allergic reaction to any product containing Factor VIII (FVIII), or have been told you have inhibitors to FVIII, as AFSTYLA might not work for you. Inform your healthcare provider of all medical conditions and problems you have, as well as all medications you are taking.

Immediately stop treatment and contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.

Your body can make antibodies, called inhibitors, against FVIII, which could stop AFSTYLA from working properly. You might need to be tested for inhibitors from time to time. Contact your healthcare provider if bleeding does not stop after taking AFSTYLA.

In clinical trials, dizziness and allergic reactions were the most common side effects. However, these are not the only side effects possible. Tell your healthcare provider about any side effect that bothers you or does not go away.

Please see full prescribing information for AFSTYLA, including patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.

AFSTYLA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.

AFSTYLA® is a registered trademark of CSL Behring Lenggau AG.

Biotherapies for Life® is a registered trademark of CSL Behring LLC.

©2021 CSL Behring LLC. The product information presented on this invitation is intended for US residents only. USA-AFS-0024-FEB21

CSL Behring
Biotherapies for Life®

AFSTYLA®
Antihemophilic Factor
(Recombinant), Single Chain